Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer
- PMID: 24740199
 - PMCID: PMC4082406
 - DOI: 10.1158/1055-9965.EPI-13-0962
 
Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer
Abstract
Survival in epithelial ovarian cancer (EOC) is influenced by the host immune response, yet the key genetic determinants of inflammation and immunity that affect prognosis are not known. The nuclear factor-κB (NF-κB) transcription factor family plays an important role in many immune and inflammatory responses, including the response to cancer. We studied common inherited variation in 210 genes in the NF-κB family in 10,084 patients with invasive EOC (5,248 high-grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous) from the Ovarian Cancer Association Consortium. Associations between genotype and overall survival were assessed using Cox regression for all patients and by major histology, adjusting for known prognostic factors and correcting for multiple testing (threshold for statistical significance, P < 2.5 × 10(-5)). Results were statistically significant when assessed for patients of a single histology. Key associations were with caspase recruitment domain family, member 11 (CARD11) rs41324349 in patients with mucinous EOC [HR, 1.82; 95% confidence interval (CI), 1.41-2.35; P = 4.13 × 10(-6)] and tumor necrosis factor receptor superfamily, member 13B (TNFRSF13B) rs7501462 in patients with endometrioid EOC (HR, 0.68; 95% CI, 0.56-0.82; P = 2.33 × 10(-5)). Other associations of note included TNF receptor-associated factor 2 (TRAF2) rs17250239 in patients with high-grade serous EOC (HR, 0.84; 95% CI, 0.77-0.92; P = 6.49 × 10(-5)) and phospholipase C, gamma 1 (PLCG1) rs11696662 in patients with clear cell EOC (HR, 0.43; 95% CI, 0.26-0.73; P = 4.56 × 10(-4)). These associations highlight the potential importance of genes associated with host inflammation and immunity in modulating clinical outcomes in distinct EOC histologies.
©2014 American Association for Cancer Research.
Conflict of interest statement
Figures
              
              
              
              
                
                
                References
- 
    
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
 
 - 
    
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. - PubMed
 
 - 
    
- Riggs JE. Rising ovarian cancer mortality in the elderly: a manifestation of differential survival. Gynecol Oncol. 1995;58:64–67. - PubMed
 
 - 
    
- du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer. 2009;115:1234–1244. - PubMed
 
 - 
    
- Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol. 1998;25:305–314. - PubMed
 
 
Publication types
MeSH terms
Substances
Grants and funding
- R01-CA61107/CA/NCI NIH HHS/United States
 - R01-CA092044/CA/NCI NIH HHS/United States
 - U01 CA069417/CA/NCI NIH HHS/United States
 - R01 CA050385/CA/NCI NIH HHS/United States
 - R25 CA092049/CA/NCI NIH HHS/United States
 
- R01-CA067262/CA/NCI NIH HHS/United States
 - N01 PC067010/PC/NCI NIH HHS/United States
 - C490/A6187/CRUK_/Cancer Research UK/United Kingdom
 - P01-CA017054/CA/NCI NIH HHS/United States
 - C536/A13086/CRUK_/Cancer Research UK/United Kingdom
 - P30 CA016056/CA/NCI NIH HHS/United States
 - R01 CA087538/CA/NCI NIH HHS/United States
 - R01 CA136924/CA/NCI NIH HHS/United States
 - K22-CA138563/CA/NCI NIH HHS/United States
 - R01 CA067262/CA/NCI NIH HHS/United States
 - R01 CA106414/CA/NCI NIH HHS/United States
 - P30 CA072720/CA/NCI NIH HHS/United States
 - C490/A10119/CRUK_/Cancer Research UK/United Kingdom
 - C536/A6689/CRUK_/Cancer Research UK/United Kingdom
 - P30 CA168524/CA/NCI NIH HHS/United States
 - N01-CN55424/CN/NCI NIH HHS/United States
 - R37-CA070867/CA/NCI NIH HHS/United States
 - R03-CA113148/CA/NCI NIH HHS/United States
 - R03 CA113148/CA/NCI NIH HHS/United States
 - R01 CA058598/CA/NCI NIH HHS/United States
 - R37 CA070867/CA/NCI NIH HHS/United States
 - R01-CA112523/CA/NCI NIH HHS/United States
 - R01-CA049449/CA/NCI NIH HHS/United States
 - R01-CA080742/CA/NCI NIH HHS/United States
 - K22 CA138563/CA/NCI NIH HHS/United States
 - N01-PC067010/PC/NCI NIH HHS/United States
 - R01 CA058860/CA/NCI NIH HHS/United States
 - C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
 - P20 GM103418/GM/NIGMS NIH HHS/United States
 - R01 CA080742/CA/NCI NIH HHS/United States
 - P30-CA072720/CA/NCI NIH HHS/United States
 - R01-CA126841/CA/NCI NIH HHS/United States
 - R01-CA058598/CA/NCI NIH HHS/United States
 - R01 CA074850/CA/NCI NIH HHS/United States
 - R01-CA122443/CA/NCI NIH HHS/United States
 - C5047/A10692/CRUK_/Cancer Research UK/United Kingdom
 - K07 CA092044/CA/NCI NIH HHS/United States
 - R01-CA087538/CA/NCI NIH HHS/United States
 - R01-CA014089/CA/NCI NIH HHS/United States
 - P50 CA105009/CA/NCI NIH HHS/United States
 - N01 PC035137/CA/NCI NIH HHS/United States
 - R01-CA074850/CA/NCI NIH HHS/United States
 - P20-GM103418/GM/NIGMS NIH HHS/United States
 - U19-CA148537/CA/NCI NIH HHS/United States
 - C490/A10124/CRUK_/Cancer Research UK/United Kingdom
 - C5047/A8384/CRUK_/Cancer Research UK/United Kingdom
 - R01 CA128978/CA/NCI NIH HHS/United States
 - R01-CA061132/CA/NCI NIH HHS/United States
 - CA115195/CA/NCI NIH HHS/United States
 - C1287/A 10710/CRUK_/Cancer Research UK/United Kingdom
 - R01-CA064277/CA/NCI NIH HHS/United States
 - P30 CA076292/CA/NCI NIH HHS/United States
 - R01 CA064277/CA/NCI NIH HHS/United States
 - R01-CA050385/CA/NCI NIH HHS/United States
 - P30 CA014089/CA/NCI NIH HHS/United States
 - U19 CA148537/CA/NCI NIH HHS/United States
 - MOP-86727/CAPMC/ CIHR/Canada
 - P50-CA105009/CA/NCI NIH HHS/United States
 - R01 CA083918/CA/NCI NIH HHS/United States
 - U01-CA069417/CA/NCI NIH HHS/United States
 - R01-CA136924/CA/NCI NIH HHS/United States
 - P01-CA15083/CA/NCI NIH HHS/United States
 - R03 CA115195/CA/NCI NIH HHS/United States
 - U01-CA071966/CA/NCI NIH HHS/United States
 - R01-CA017054/CA/NCI NIH HHS/United States
 - R01 CA054419/CA/NCI NIH HHS/United States
 - R01 CA122443/CA/NCI NIH HHS/United States
 - P30 CA015083/CA/NCI NIH HHS/United States
 - C5047/A15007/CRUK_/Cancer Research UK/United Kingdom
 - R01-CA016056/CA/NCI NIH HHS/United States
 - R21-GM86689/GM/NIGMS NIH HHS/United States
 - C1312/A15589/CRUK_/Cancer Research UK/United Kingdom
 - R01 CA076016/CA/NCI NIH HHS/United States
 - R01-CA083918/CA/NCI NIH HHS/United States
 - K07 CA143047/CA/NCI NIH HHS/United States
 - K07-CA143047/CA/NCI NIH HHS/United States
 - R01-CA149429/CA/NCI NIH HHS/United States
 - CA106414/CA/NCI NIH HHS/United States
 - R01 CA087696/CA/NCI NIH HHS/United States
 - CA054419/CA/NCI NIH HHS/United States
 - U19 CA148112/CA/NCI NIH HHS/United States
 - R01 CA149429/CA/NCI NIH HHS/United States
 - P30-CA168524/CA/NCI NIH HHS/United States
 - R01-CA071766/CA/NCI NIH HHS/United States
 - P01 CA017054/CA/NCI NIH HHS/United States
 - P01-CA087696/CA/NCI NIH HHS/United States
 - 13086/CRUK_/Cancer Research UK/United Kingdom
 - N01 CN025403/CA/NCI NIH HHS/United States
 - R01-CA128978/CA/NCI NIH HHS/United States
 - R21 GM086689/GM/NIGMS NIH HHS/United States
 - R01-CA114343/CA/NCI NIH HHS/United States
 - R01 CA049449/CA/NCI NIH HHS/United States
 - R01-CA076016/CA/NCI NIH HHS/United States
 - U19-CA148112/CA/NCI NIH HHS/United States
 - R37-CA70867/CA/NCI NIH HHS/United States
 - K07-CA095666/CA/NCI NIH HHS/United States
 - R01 CA063682/CA/NCI NIH HHS/United States
 - R01-CA061107/CA/NCI NIH HHS/United States
 - P50-CA136393/CA/NCI NIH HHS/United States
 - K07 CA095666/CA/NCI NIH HHS/United States
 - C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
 - N01-PC035137/PC/NCI NIH HHS/United States
 - R01 CA112523/CA/NCI NIH HHS/United States
 - P50 CA136393/CA/NCI NIH HHS/United States
 - R01 CA126841/CA/NCI NIH HHS/United States
 - A10124/CRUK_/Cancer Research UK/United Kingdom
 - R01 CA114343/CA/NCI NIH HHS/United States
 - R01-CA058860/CA/NCI NIH HHS/United States
 - R01-CA080978/CA/NCI NIH HHS/United States
 - 16561/CRUK_/Cancer Research UK/United Kingdom
 - 10124/CRUK_/Cancer Research UK/United Kingdom
 
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
